FDA Approves Selumetinib for Paediatric Patients 1 Year of Age and Older with Neurofibromatosis Type 1 with Symptomatic, Inoperable Plexiform Neurofibromas By Ogkologos - September 25, 2025 386 0 Facebook Twitter Google+ Pinterest WhatsApp Approval was based on findings from the Study 89, SPRINT and the SPRINKLE trials Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR A Pet Pug Helped Two Sisters Realize They Both Had Breast... October 16, 2020 New Study Finds Dogs Can Sniff Out Lung Cancer — And... April 10, 2019 Belantamab Mafodotin–Containing Triplets Confer a Significant PFS Benefit Among Previously Treated... July 3, 2024 FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or... March 27, 2025 Load more HOT NEWS Efficacy and Safety of Trastuzumab and Pertuzumab in Combination with FLOT... Man Who Lost His Mother to Breast Cancer Opens Resource Center... After Misdiagnosis, Mom Found Out She Had Terminal Breast Cancer Shortly... ΙΣΤΟΡΙΑ
